Ergothioneine

What is known

A canine experiment found that adding ergothioneine to semen extender altered post-thaw sperm motility and oxidative-stress measures, but this was an ex vivo cryopreservation intervention rather than oral supplementation of dogs and did not establish fertility outcomes. In humans, oral ergothioneine is absorbed, but an early controlled pharmacokinetic study found that most oxidative-damage and inflammatory biomarker changes were nonsignificant. A later randomized pilot in people with mild cognitive impairment produced preliminary cognitive findings but was very small. Observational human studies linking circulating ergothioneine with lower disease or mortality risk remain associative. In male mice, supplementation has been reported to extend lifespan and improve multiple aging-related phenotypes, providing notable non-canine evidence but not direct evidence for dogs.

What is not known

No verified living-dog oral intervention trial demonstrating healthy-aging, cognitive, physical or disease outcomes was identified through the evidence cutoff. The canine semen study is ex vivo and cannot establish systemic bioavailability, safety or efficacy. The human cognitive intervention evidence remains pilot-scale. Human epidemiologic associations cannot distinguish ergothioneine itself from diet quality, correlated exposures or other confounding factors. The prominent lifespan experiment is in male mice, not dogs, and therefore provides translational plausibility rather than canine lifespan evidence.